Originally a pharmaceutical used to control bleeding, Tranexamic Acid (TXA) has become one of the most talked-about ingredients in modern skincare for its ability to tackle melasma and hyperpigmentation through a unique mechanism — inhibiting the plasmin pathway that triggers melanin overproduction after UV exposure.
Tranexamic Acid (INCI: TRANEXAMIC ACID, CAS 1197-18-8) is a synthetic amino acid derivative originally developed as an antifibrinolytic medication to reduce excessive bleeding. In dermatology, it has gained significant attention for its depigmenting properties, particularly in the treatment of melasma — a notoriously difficult-to-treat pigmentary disorder. It is registered in the EU CosIng database (#80291) with the function of skin conditioning.
Unlike traditional brightening ingredients that directly inhibit tyrosinase (such as Alpha Arbutin or Vitamin C), Tranexamic Acid works through the plasminogen/plasmin pathway. UV radiation activates plasmin in keratinocytes, which in turn triggers the release of arachidonic acid and prostaglandins — signalling molecules that stimulate melanocytes to produce melanin. By blocking plasminogen activator, TXA interrupts this cascade at an earlier stage, making it particularly effective for UV-driven and hormonal pigmentation such as melasma.
Clinical studies and systematic reviews support the use of TXA for melasma, both as a standalone treatment and as an adjunct to other therapies. A 2017 meta-analysis found that TXA (oral, topical, and other routes combined) was associated with reduced melasma area and severity index (MASI) scores, though results varied by formulation, concentration, and combination therapy. For topical use, concentrations of 2–5% are most common in the literature, with treatment durations of 8 to 12 weeks. The topical form is favoured in cosmetic products due to minimal systemic absorption. Our database identifies Tranexamic Acid in 1,240 product variants, making it one of the most widely used brightening actives in K-beauty and global skincare.
TXA targets melasma through a different pathway than most brightening agents. By blocking plasmin-mediated UV signalling that drives melanocyte activation, it addresses the trigger rather than just inhibiting melanin synthesis downstream. Clinical studies have reported MASI score improvements after 8–12 weeks of topical use at 2–5%, though results vary by formulation and individual.
Post-acne marks and other PIH respond well to TXA because inflammation-driven pigmentation shares similar signalling pathways with UV-triggered melanogenesis. TXA helps prevent new dark spots from forming while gradually fading existing ones.
Because TXA works through a different mechanism (plasmin pathway) than tyrosinase inhibitors (Alpha Arbutin, Kojic Acid) or melanin-transfer blockers (Niacinamide), it stacks synergistically with these ingredients for a multi-targeted approach to uneven skin tone.
TXA does not cause exfoliation, photosensitivity, or direct melanocyte toxicity. It is generally well-tolerated and does not typically produce the irritation associated with exfoliating acids or retinoids, making it suitable for daily use and compatible with sensitive skin routines.
Generally suitable for: All skin types, including sensitive and acne-prone skin. Especially valued by those dealing with melasma, sun spots, or post-inflammatory hyperpigmentation. No photosensitivity risk — can be used morning and evening.
Tranexamic Acid is permitted in EU cosmetics without concentration restrictions. It has no known allergen flags, no CIR concerns on record, and its non-irritating mechanism of action means it is generally well-tolerated. A GHS hazard classification related to eye irritation (H319) has been identified, which is relevant for products used near the eye area.
Eye irritation: Tranexamic Acid carries a GHS H319 classification (causes serious eye irritation). While this does not affect general facial application, avoid getting products containing TXA directly into the eyes. If using a serum near the orbital area, apply carefully and rinse immediately if irritation occurs.
Pharmaceutical origin: Oral Tranexamic Acid is a prescription medication with systemic effects (antifibrinolytic — reduces bleeding). The topical cosmetic form has minimal systemic absorption. If you are currently taking oral TXA, are pregnant or nursing, or have a history of thrombosis, consult your healthcare provider before using topical TXA products.
No official cosmetic safety assessment: Neither the SCCS nor CIR has published a dedicated safety opinion for Tranexamic Acid in cosmetics. Our rating relies on the EU CosIng registration (no restrictions), GHS hazard data, the extensive pharmaceutical safety profile, and published dermatological studies on topical use.
Topical Tranexamic Acid has limited systemic absorption and is generally considered low-risk for external use. However, there are no dedicated studies on the safety of topical TXA during pregnancy or lactation. Animal studies on oral TXA have not shown evidence of fetal harm, but adequate human data are lacking. Given that melasma often worsens during pregnancy, some individuals may be particularly interested in TXA — but should consult their healthcare provider before use. Alternatives with more established pregnancy safety profiles (such as Niacinamide or Azelaic Acid) may be considered.
Start with a gentle cleanser. Clean skin allows better penetration of active ingredients like TXA.
Apply a few drops of your TXA serum (typically 2–5%) to the face, focusing on areas with dark spots, melasma patches, or uneven tone. Pat gently into slightly damp skin. TXA does not cause photosensitivity, so it can be used in both AM and PM routines.
For enhanced results, layer with Niacinamide or Vitamin C — they target pigmentation through different pathways. Follow with a moisturiser to lock in hydration and support the skin barrier.
Sunscreen is non-negotiable when treating hyperpigmentation. UV exposure is the primary trigger for melasma and can undo the progress made by TXA. Use broad-spectrum SPF 30+ every morning, even on cloudy days.
The most popular and effective format. Typically formulated at 2–5% concentration. Lightweight, fast-absorbing, and easy to layer with other actives in a multi-step routine.
K-beauty brands often formulate TXA in pad-type toners or essences for daily brightening. Lower concentration but convenient for consistent, gentle application.
Some formulas combine TXA with hydrating and barrier-supporting ingredients. Good for dry skin types or simplified routines where fewer products are preferred.
A powerhouse combination. Niacinamide inhibits melanosome transfer while TXA blocks the plasmin pathway upstream. Together they address pigmentation through two independent mechanisms. Both are gentle and non-irritating.
Alpha Arbutin inhibits tyrosinase — yet another distinct mechanism from TXA's plasmin pathway. The triple combination of TXA + Niacinamide + Alpha Arbutin is increasingly popular in K-beauty for comprehensive brightening.
Vitamin C provides antioxidant protection and interrupts melanin synthesis at a different step. TXA and Vitamin C can generally be used in the same routine, though compatibility ultimately depends on the overall formulation pH, vehicle, and individual skin tolerance.
Sunscreen is essential — UV exposure drives the very pathway TXA targets. Barrier-supporting ingredients like ceramides maintain skin health during active brightening treatment.
If you are currently taking oral TXA (a prescription medication), are pregnant or nursing, or have a history of thrombosis, consult your healthcare provider before adding topical TXA to your routine.
TXA itself is non-irritating, but layering it with high-concentration retinoids, AHAs, and BHAs simultaneously can overwhelm sensitive skin. If combining with potent actives, introduce them gradually and monitor for irritation.
Due to the H319 (eye irritation) classification, exercise caution when applying TXA serums close to the orbital area. Avoid direct eye contact and choose products specifically formulated for the eye area if targeting periorbital pigmentation.
Found in 1,240 product variants in our database. Here are some well-known options. Note: formulations may change over time — always check the current INCI list on the product packaging.
Scan your skincare products and get instant ingredient analysis with SkinSenseDiary.
Download the App